Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Merger or Acquisition (February 2024)
12 slides from Telix Pharmaceuticals's merger presentation, Feb 8, 2024
Slide 1: QSAM Biosciences Acquisition Transaction Overview
QSAM Biosciences Acquisition Transaction Overview Telix Pharmaceuticals (ASX:TLX) 8 February 2024 SPECT/CT scan of metastatic breast cancer patient showing bone tumour uptake of 153Sm-DOTMP
Slide 2: Executive summary: QSAM Biosciences, Inc
Executive summary: QSAM Biosciences, Inc Highly complementary addition to Telix’s therapeutic pipeline About the Company About the Technology • Austin, TX-based company • “Next generation” bone seeking • Launched in 2019, U.S. OTC-listed targeted radiopharmaceuticals • Founded by a scientific leader
Slide 3: What is 153Sm-DOTMP?
What is 153Sm-DOTMP? Next generation bone seeking radiopharmaceutical • DOTMP ((1,4,7,10-Tetraazacyclododecane- 1,4,7,10 tetrayl) tetrakis (methylene)) tetraphosphonic acid • A chelator containing phosphonic acid groups • Efficiently complexes with several therapeutically useful isotopes, including
Slide 4: 153Sm-DOTMP: third generation bone seeking radiopharmaceutical
153Sm-DOTMP THIRD generation bone seeking radiopharmaceutical GENERATION 3 GENERATION 1 GENERATION 2 • 153Sm-DOTMP • Quadramet®1 (153Sm-EDTMP) • Xofigo® (223Ra) launched as a • Far more efficient chelator than and Metastron®1 (89Sr) last-line bone seeking agent with EDTMP, less chelant and much Rx a
Slide 5: 153Sm is a highly suitable isotope for this application
153Sm is a highly suitable isotope for this application When used with suitable bone-seeking chelators • Low average beta energy (230keV) and a shorter half-life of 1.9 days (compared to 6.6 days and 440keV for 177Lu) means more controlled radiation dose and the ability to give multiple doses more f
Slide 6: DOTMP Bone-seeking chelator
DOTMP Bone-seeking chelator Transforms this application EDTMP (“Old” – Quadramet®) DOTMP (“New”) • Very low chelating efficiency • Much more efficient chelator • EDTMP requires a 273:1 or greater ligand-to-metal • Binds at a ratio of 1.5:1 to 3:1 with the ability to bind ratio which results in a lar
Slide 7: Clinical utility: Palliative care
Clinical utility: Palliative care Significant unmet medical need Palliative utility (low dose, single dose) • Relief from pain due to bony (osteoblastic) metastases needs new, cost-effective solutions • SoC (bisphosphonates, steroids, opioids) offers a low quality of life (QoL) for patients. EBRT1 i
Slide 8: Clinical utility: Osteosarcoma
Clinical utility: Osteosarcoma Potential upside, proof-of-concept demonstrated Therapeutic utility: (high(er) dose, repeat dosing) • Osteosarcoma is a rare cancer of the bone, most common in children, adolescents and young adults • 153Sm-DOTMP has demonstrated clear anti-bone tumour effect in pre-cl
Slide 9: Addressable market
Addressable market Potential market is significant Overall landscape Commercial entry-point • 50% of adult cancers result in the Bone metastases occurs when • ~150,000 men in the U.S. are presence of bone metastases cancer cells spread from their living with metastatic prostate original site to a bo
Slide 10: Asset development plan overview
Asset development plan overview Rapid pathway to commercialisation • Current Phase I bone metastases Highly strategic ✓ therapeutic trial establishes basic safety / dosing (including repeat dosing) – • Telix’s U.S. commercial team completion in H2 2024 already provides Illuccix® to hospitals and inf
Slide 11: Synergies with Telix's portfolio strategy
Synergies with Telix’s portfolio strategy This is highly aligned – across the portfolio, builds depth in key focus areas Prostate Cancer Brain Cancer Sarcoma – QoL1 management Early Stage TLX101 Disease TLX591 / 2 Pluvicto® (Telix) (Telix) (Novartis) TLX300 QSAM Glioblastoma (Telix) (therapy) Sarcom
Slide 12: Summary
Summary Rapid commercialisation, highly aligned • Reinforces Telix’s commitment to prostate cancer • Potential to expand into other cancer areas either palliatively (breast cancer) or therapeutically (osteosarcoma) • Highly aligned with Telix’s overall portfolio and areas of clinical strength • Pote
Telix Pharmaceuticals — Merger or Acquisition (February 2024) on 6ix